How many drugs treat Bacteroides Peritonitis?

Drug Landscape tracks 8 marketed treatments for Bacteroides Peritonitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/bacteroides-peritonitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Bacteroides Peritonitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bacteroides Peritonitis (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Bacteroides Peritonitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Merrem	Meropenem	Pfizer	meropenem		1996-01-01
Zosyn	TAZOBACTAM	Merck Sharp & Dohme B.V.	beta Lactamase Inhibitor		1993-01-01
Unasyn	SULBACTAM	Pfizer	beta Lactamase Inhibitor	Serine beta-lactamase-like protein LACTB, mitochondrial	1986-01-01
Augmentin 250	CLAVULANIC ACID	Dr Reddys Labs Inc	beta Lactamase Inhibitor		1984-01-01
Unasyn	AMPICILLIN	Bristol-Myers Squibb	Penicillin-class Antibacterial	Transient receptor potential cation channel subfamily M member 4	1965-01-01
Metro I.V. In Plastic Container	METRONIDAZOLE	Baxter	Nitroimidazole Antimicrobial [EPC]		1963-01-01
Merrem	Merrem	National Institutes of Health Clinical Center (CC)		Beta-lactamase, Beta-lactamase NDM-1, Beta-lactamase class B VIM-2
Metronidazol	Metronidazol	University of Oslo		Thioredoxin reductase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 6 drugs in Bacteroides Peritonitis
Pfizer · 2 drugs in Bacteroides Peritonitis
Bristol-Myers Squibb · 1 drug in Bacteroides Peritonitis
Dr Reddys Labs Inc · 1 drug in Bacteroides Peritonitis
Merck Sharp & Dohme B.V. · 1 drug in Bacteroides Peritonitis
National Institutes of Health Clinical Center (CC) · 1 drug in Bacteroides Peritonitis
University of Oslo · 1 drug in Bacteroides Peritonitis
Baxter · 1 drug in Bacteroides Peritonitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Bacteroides Peritonitis:

Cite this brief

Drug Landscape (2026). Bacteroides Peritonitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bacteroides-peritonitis. Accessed 2026-06-10.

Bacteroides Peritonitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing